Key Players
Competitive Landscape
CBD gummies place direct-to-consumer brands beside public CBD platforms and manufacturing-backed operators whose products must pass retailer documentation checks. Buyer review is shifting from flavor variety toward cannabinoid specifications and current batch records. Online reach does not overcome jurisdictions that block direct shipment of the same formula. Companies with controlled manufacturing or current laboratory records are answering retailer qualification faster because declared strength remains traceable to a tested batch.
Recent company actions are concentrating competitive attention on channel-access programs and consolidation among established CBD platforms. Charlotte's Web launched Route CBD in August 2026 in response to California restrictions on affected full-spectrum products. cbdMD closed its Bluebird Botanicals asset acquisition in January 2026 and gained additional brand plus regulatory assets. Medterra entered a non-binding merger LOI in March 2026 that expired in May without closing. High Tide began evaluating Medicare-aligned pathways for FAB CBD during March 2026 following its membership in the National Compassionate Care Council.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| August 2026: Charlotte's Web launched Route CBD along the California-Nevada border in response to California restrictions on affected full-spectrum products. | Loss of lawful direct access in a major state. | Brands are building jurisdiction-specific access responses. | Use compliant nearby channels and education programs in jurisdictions that block direct shipment. |
| March 2026: High Tide joined the National Compassionate Care Council and said FAB CBD was exploring Medicare-aligned CBD pathways. | Healthcare programs require documented eligibility and evidence before CBD products can enter institutional routes. | Established USA CBD brands are testing regulated healthcare access alongside direct e-commerce. | Prepare product documentation for healthcare purchasing routes when program rules permit eligible CBD products. |
| March 2026: Splash Beverage Group and Medterra entered a non-binding merger LOI that later expired without closing. | CBD operators continue seeking capital and public-market combinations. | Consolidation attempts remain selective and execution risk is visible. | Well-capitalized operators can pursue assets without treating an announced transaction as completed capacity. |
| January 2026: cbdMD closed the acquisition of substantially all Bluebird Botanicals assets. | Brands seek trusted customer bases and regulatory documentation. | CBD platforms are consolidating brand and compliance assets. | Shared distribution and operating infrastructure can support additional CBD product routes as integration progresses. |
Green Roads and Joy Organics are competing through current CBD gummy lines and testing evidence. Cornbread Hemp and Koi CBD are using manufacturing or retail routes distinct from the dated actions in the development map. CV Sciences remains active through its current gummy portfolio and retail presence.
Source: Future Market Insights, CBD Gummies Market Report, 2026-2036.
The leading companies csovers direct-to-consumer and wholesale routes alongside healthcare access programs and tested United States gummy manufacturing capacity.
Who leads the CBD gummies market?
No single company can be ranked first from comparable public share data under this market definition. Competitive separation is more visible in testing records and channel access than in comparable company share disclosure.
Which companies have documented qualification or quality approvals?
Hemp Bombs is supported by Global Widget facilities that document GMP and NSF certifications plus USDA Organic and UL credentials. Charlotte's Web reported zero findings on its most recent NSF 455-2 dietary-supplement cGMP audit in March 2026.
Which companies provide broad-spectrum or full-spectrum CBD gummy products?
Charlotte's Web and cbdMD document multiple CBD gummy routes that include full-spectrum or THC-free options in current materials. Joy Organics plus Koi CBD and CV Sciences also document broad-spectrum or full-spectrum gummy routes under their active portfolios.
Which companies document North American and international channel activity?
Charlotte's Web and cbdMD document current United States retail plus direct-to-consumer activity under the defined CBD gummy scope. Medterra documents worldwide wholesale distribution for its CBD portfolio in current retail-partner materials published on its website.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Charlotte's Web Holdings, Inc. | Multi-channel hemp wellness company with current full-spectrum access programs and public policy activity. | In August 2026, the company launched Route CBD to provide education and legal access opportunities along the California-Nevada border. |
| cbdMD, Inc. | Science-led CBD platform with direct-to-consumer, retail and emerging healthcare routes. | In January 2026, cbdMD closed the acquisition of substantially all Bluebird Botanicals assets and added brand, distribution and regulatory documentation. |
| Medterra CBD, LLC | Cannabinoid wellness operator serving United States and international customers through direct and multi-brand routes. | In March 2026, Medterra entered a non-binding merger LOI with Splash Beverage Group. The LOI later expired in May without a closing. |
| FAB CBD | United States e-commerce CBD brand owned by High Tide with gummies in its hemp-derived wellness portfolio. | In March 2026, High Tide joined the National Compassionate Care Council and said FAB CBD was exploring Medicare-aligned CBD pathways. |
Research Methodology
The company overview covers current CBD gummy routes supported by public filings and official company announcements. Each dated action stays with the company or parent that completed it and retains the reported event state. Current testing and manufacturing records support capability claims tied directly to CBD gummies. The overview includes related CBD activity only for a documented shared qualification or purchase route. The mapping does not treat a proposed transaction as completed capacity and does not use product catalogs as dated developments.
